Encrantz Staffan reported grant involving 28,261 shares of Sight Sciences, Inc. at $0.00 for $0 on Jun 4, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Director
DIR
Filed Jun 5, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$0Shares × reported price
Shares traded
28,261Common Stock
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
1,420,183Direct
Trade date
Jun 4, 2026Grant
Filed
Jun 5, 2026, 4:10 PM ET1-day reporting delay
Accession
0001193125-26-259570Code A · Transaction 99804
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

SGHT price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
SGHT · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −2.7%1w ago +13%1d ago −2.5%
Returns since7d +15%30d +22%90d180d1y

Footnotes in full

F1: Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's Non-Employee Director Compensation Program. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The number of RSUs granted is equal to approximately $130,000 of shares of Common Stock as determined by the closing price on the grant date, June 4, 2026. The RSUs vest on the earlier of June 4, 2027 and the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service as a director on the Company's board of directors through such vesting date. F2: Includes (i)1,391,922 shares of Common Stock and (ii) 28,261 RSUs which are subject to vesting as reported herein. F3: These shares of Common Stock are held of record by the 1997 Staffan Encrantz and Margareta Encrantz Revocable Trust (the "Trust"). The Reporting Person is a trustee of the Trust and may be deemed to beneficially own the shares held by the Trust for purposes of Rule 13d-3 under the Securities Exchange Act of 1934 (the "Exchange Act"). The Reporting Person disclaims beneficial ownership of the shares held by the Trust (and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 under the Exchange Act or for any other purpose), except to the extent of his pecuniary interest therein, if any. F4: These shares of Common Stock are held of record by Allegro Investment Fund, L.P. ("Allegro Investment Fund"). The Reporting Person is the Chairman and CEO and sole director of Allegro Investment Inc., which is the investment manager of Allegro Investment Fund, and may be deemed to beneficially own the shares held by Allegro Investment Fund for purposes of Rule 13d-3 under the Exchange Act. However, the Reporting Person does not have any pecuniary interest in the shares held by Allegro Investment Fund and disclaims beneficial ownership with respect to all such shares. Accordingly, these shares are being reported in this report voluntarily by the Reporting Person for informational purposes only and shall not be deemed an admission that the Reporting Person is the beneficial owner of any such shares for purposes of Section 16 under the Exchange Act or for any other purpose.